Fundraising Fox
/Companies
Sign in

Monod Bio

Seattle, US · Founded 2020 · Delaware corporation · 27 employees on LinkedIn · 2 known investors

Find your way into Monod Bio

Monod Bio is a University of Washington spin-out that uses AI-powered de novo protein design to develop research-use-only tools and in vitro diagnostics. It operates in the life sciences and medical diagnostics sector.

AI & Machine LearningBiotechMedical Devices

Founders & leadership

Monod Bio was founded in 2020 by Daniel Adriano Silva Manzano, Alfredo Quijano Rubio, and Daniel Silva Manzano.

DADaniel Adriano Silva Manzano
Daniel Adriano Silva ManzanoCo-founder
AQAlfredo Quijano Rubio
Alfredo Quijano RubioCo-Founder, Chief Scientific Officer (CSO)
DSDaniel Silva Manzano
Daniel Silva ManzanoCo-Founder, CEO, Board Member
GTGreg Tibbitts
Greg TibbittsFractional CFO
DJ
Dave JohnsonNamed on SEC filing
DS
David ShoultzNamed on SEC filing
BM
Berta Melina CimlerNamed on SEC filing

Investors · 2

Pack Ventureslisted by Pack VenturesSeattle

How we know: Pack Ventures's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$30.2M disclosed across 2 of 3 rounds · 2021–2024

▶$24.2MraisedJun 2022 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alfredo Quijano RubioExecutive Officer
  • Daniel Adriano Silva ManzanoExecutive Officer, Director
  • Karan TakharDirector
  • Dave JohnsonDirector
  • Berta Melina CimlerDirector
  • David A ShoultzExecutive Officer, Director
Offering amount
$26.3M
Amount sold
$24.2M
First sale
Jun 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedDec 2021 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel Adriano Silva ManzanoExecutive Officer, Director
  • Dave JohnsonDirector
  • David ShoultzExecutive Officer, Director
  • Alfredo Quijano RubioExecutive Officer
  • Berta Melina CimlerDirector
Offering amount
$6.1M
Amount sold
$6M
First sale
Nov 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

ManifoldManifold Bio combines AI-guided protein design with high-throughput in vivo screening to engineer tissue-targeted biologics and deliver therapeutic payloads to specific organs. The company develops a computational and experimental platform to optimize pharmacokinetics and biodistribution directly in living systems for drug discovery and development.
TRACERTRACER offers customized data quality services and analysis, emphasizing precision and speed to support faster decision-making for clients.

Companies working in the same space as Monod Bio.

In the news

Monod Bio Receives $1.5M Grant to Develop NovoBodies™ for Next-Generation Tuberculosis Diagnostics - Monod Biomonod.bio · Sep 2025Institute for Protein Design spinout Monod Bio raises $25M for molecular biosensors - Monod Biomonod.bio · Mar 2024Monod Bio Raises $25M in Seed Financing - FinSMEsfinsmes.com · Aug 2022Monod Bio Closes $25M Seed Financing to Advance Biosensor Technology Platform - BioSpacebiospace.com · Aug 2022

Frequently asked questions

What does Monod Bio do?
Monod Bio is a University of Washington spin-out that uses AI-powered de novo protein design to develop research-use-only tools and in vitro diagnostics. It operates in the life sciences and medical diagnostics sector.
Who founded Monod Bio?
Monod Bio was founded by Daniel Adriano Silva Manzano, Alfredo Quijano Rubio, Daniel Silva Manzano in 2020.
Who are Monod Bio's investors?
Monod Bio's investors include Global Health Investment Corporation, Pack Ventures.
How much funding has Monod Bio raised?
Monod Bio has disclosed $30.2M raised across 2 of its 3 known rounds.
Where is Monod Bio headquartered?
Monod Bio is headquartered in Seattle, US.